PACT COVID-19 Update
Many pulmonary fibrosis trials have been suspended whilst respiratory health professionals were called to the frontline of the COVID-19 response. We thank all those who have and continue to work on the frontline.
PACT is pleased to update that due to the improved clinical situation of COVID-19 in Australasia some trials are beginning to recommence. Recruiting trials listed below remain ongoing and some sites are starting to accept new trial enrolments. For everyone’s safety, extraordinary measures continue to be in place for patients in trails.
Please continue to check our website for trial updates, we hope to be able to reopen trial enquiries soon. Alternatively, become a member to stay up to date.Become a member
Over the past decade high quality trials have transformed treatment approaches for patients with PF both by ensuring patients are not exposed to potentially harmful treatments and by supporting access to treatments with proven efficacy. Find out more in the Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia, here.
Enrollment in clinical trails is now considered standard of care for patients with pulmonary fibrosis, much as it is for patients with cancer. Clinicians – be they PF ‘experts’ or not – have a vital role to play in encouraging enrollment in high quality clinical trials, especially since PF is an uncommon disease impeding recruitment to very large trials. Below are links to Pulmonary Fibrosis trials currently recruiting in Australasia.
|Isabela 1&2||A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With ldiopathic Pulmonary Fibrosis||Recruiting||Trial Summary
Study ID: NCT0371l-162
|PFOX||PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial||Recruiting||Trial Summary Study Id: NCT03737409|
|HIIT||High intensity interval training in fibrotic interstitial lung disease||Recruiting||Trial Summary
Study Id: NCT03800914
|GRIPF||Genetic research in Idiopathic Pulmonary Fibrosis (GRIPF)||Recruiting||Trial Summary
|HHF-ILD||Handheld fan for breathlessness in interstitial lung disease||Recruiting||Trial Summary
Study Id: ACTRN12618001838202
Trials in Follow Up
|ATLAS||A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis||Closed to recruitment||Trial Summary
Study Id: ACTRN12618001838202
|Trail1||A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease (RAILD)||Closed to recruitment||Trial Summary Study ID: NCT02808871|
|COLDICE||Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease allianCE||Study completed||Trial Summary
Study Id: ACTRN12615000718549
|SPIRIT||A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Study completed||Trial Summary
Study ID: NCT03573505
|SCENIC||Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial||Discontinued
The SCENIC study was terminated due to the impact of COVID-19. The study was being conducted across 11 countries and while the impact was minimal in Australasia this was not the case in the other regions.